The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Clinical laboratory mutation analysis performed on aggressive B cell non-Hodgkin lymphoma patient biopsies.
 
Daniel J Landsburg
Consulting or Advisory Role - ADC Therapeutics; Epizyme; Incyte; Karyopharm Therapeutics; MorphoSys
Speakers' Bureau - Seagen
Research Funding - Curis (Inst); Takeda (Inst); Triphase Accelerator Corp (Inst)
Other Relationship - Karyopharm Therapeutics
 
Gabriel C. Caponetti
No Relationships to Disclose
 
Adam Bagg
No Relationships to Disclose
 
Stephen J. Schuster
Consulting or Advisory Role - Acerta Pharma/AstraZeneca; BeiGene; Celgene; Genentech/Roche; Incyte; Janssen; Legend Biotech; Loxo; MorphoSys; MustangBio; Nordic Nanovector; Novartis; Regeneron
Research Funding - Abbvie (Inst); Adaptive Biotechnologies (Inst); Celgene (Inst); DTRM (Inst); Genentech/Roche (Inst); Incyte (Inst); Juno Therapeutics (Inst); Merck (Inst); Novartis (Inst); Pharmacyclics (Inst); TG Therapeutics (Inst)
Patents, Royalties, Other Intellectual Property - Patent Combination Therapies of CAR and PD-1 Inhibitors (via University of Pennsylvania with royalties to Novartis)
 
Sunita Nasta
Consulting or Advisory Role - Incyte; Merck; MorphoSys
Research Funding - Aileron Therapeutics; Atara Biotherapeutics; Debiopharm Group; Forty Seven; Incyte; Millennium; Pharmacyclics/Janssen; Rafael Pharmaceuticals; Roche/Genentech
 
James M. Gerson
Consulting or Advisory Role - Abbvie; Genentech
Research Funding - Loxo
 
Dale M. Frank
No Relationships to Disclose
 
Stefan K. Barta
Honoraria - Acrotech Biopharma; Affimed Therapeutics; Daiichi Sankyo/Lilly; Kyowa Kirin International; Seagen
 
Jakub Svoboda
Consulting or Advisory Role - Adaptive Biotechnologies; ADC Therapeutics; AstraZeneca; Atara Biotherapeutics; BMS; Pharmacyclics; Seagen
Research Funding - Adaptive Biotechnologies (Inst); AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Incyte (Inst); Merck (Inst); Pharmacyclics (Inst); Seagen (Inst)
Travel, Accommodations, Expenses - AstraZeneca
 
Siddharth Bhattacharyya
No Relationships to Disclose
 
Julianne N Qualtieri
No Relationships to Disclose
 
Megan S. Lim
No Relationships to Disclose
 
Elise A. Chong
No Relationships to Disclose
 
Jacquelyn Roth
Stock and Other Ownership Interests - Lilly; Pfizer
Consulting or Advisory Role - NCI
 
Salvatore F. Priore
No Relationships to Disclose
 
Safoora Deihimi
No Relationships to Disclose
 
Jennifer J. Morrissette
No Relationships to Disclose